Janssen withdraws attempt to extend Velcade indication in EU PMLiVE The Johnson & Johnson division had submitted an application to the European Medicines Agency (EMA) in September 2011 to consider the drug's use in combination with rituximab for the treatment of patients with relapsed follicular non-Hodgkin lymphoma ... |
